RAPT Therapeutics Announces Proposed Public Offering of Common Stock

On October 21, 2025, RAPT Therapeutics, a clinical-stage immunology-based biopharmaceutical company, announced a proposed underwritten public offering of its common stock3 4.

All shares in the offering are being provided by RAPT Therapeutics itself, with no selling stockholders3 4.

The company expects to grant underwriters a 30-day option to purchase up to an additional 15% of the total shares offered at the public offering price, less underwriting discounts and commissions (also known as a 'greenshoe' option)3 4.

The size and terms of the offering were originally not disclosed and the transaction was subject to market conditions, with no assurance of completion timing or final terms at announcement3 4 6.

On October 21, 2025, RAPT announced the pricing:
8,333,334 shares at $30.00 per share, granting the underwriters a 30-day option to purchase up to an additional 1,250,000 shares at the offering price1 7 10.

Expected gross proceeds to RAPT are approximately $250 million before deductions, excluding any exercise of the underwriters’ option1 7 10.

The offering is expected to close on or about October 23, 2025, subject to customary closing conditions1 7.

The offering is being conducted pursuant to a shelf registration statement filed with the SEC that became effective in August 20232.

Leerink Partners, TD Cowen, Guggenheim Securities, Wells Fargo Securities, and LifeSci Capital are acting as joint bookrunning managers, with H.C. Wainwright & Co. and Clear Street as lead managers2 3.

RAPT’s stock had surged over 130% year-to-date ahead of the offering announcement; the event may have a dilutive effect upon existing shareholders2 4.